Stocks › VRTX
VERTEX PHARMACEUTICALS INC / MA
VRTX·Nasdaq·
United States·USD
United States·USD$502.31
-1.19 (-0.24%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
VRTX
VERTEX PHARMACEUTICALS INC / MA · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
VRTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of VRTX by members of U.S. Congress · 62 on record · 10 in the last 12 months
Whale Activity
Position changes in VRTX reported for 2026-09-30 by 3 tracked institutional filers
- Increased0
- New0
- Held0
- Decreased1
- Closed0
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| HALL LAURIE J TRUSTEE | 5,987 | $3.1M | decreased |
| Bangor Savings Bank | 4,317 | $2.3M | — |
| Financial Symmetry Inc | 760 | $397K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by VRTX insiders, by quarter · Form 4
Recent Insider Transactions
5,929 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Tatsis OuraniaEVP, Chief Reg. & Quality Off. | Sale | −1,500 | $524.99 | $787K | Jul 2, 2026 | Form 4 ↗ |
| McKechnie DuncanEVP, Chief Commercial Officer | Sale | −1,541 | $519.00 | $800K | Jul 2, 2026 | Form 4 ↗ |
| Liu JoyEVP and Chief Legal Officer | Sale | −828 | $502.71 | $416K | Jul 1, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −596 | $482.50 | $288K | Jun 26, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −1,020 | $462.17 | $471K | Jun 18, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −4,062 | $450.00 | $1.8M | Jun 15, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −1,745 | $450.00 | $785K | Jun 5, 2026 | Form 4 ↗ |
| Liu JoyEVP and Chief Legal Officer | Sale | −828 | $439.91 | $364K | Jun 1, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −1,974 | $450.00 | $888K | May 29, 2026 | Form 4 ↗ |
| Bunnage Mark E.EVP, Chief Scientific Officer | Sale | −33 | $453.45 | $15K | May 15, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −1,354 | $453.45 | $614K | May 15, 2026 | Form 4 ↗ |
| Bozic CarmenEVP and CMO | Sale | −6,988 | $450.00 | $3.1M | May 12, 2026 | Form 4 ↗ |
| Bhatia Sangeeta N.Director | Sale | −318 | $423.73 | $135K | May 4, 2026 | Form 4 ↗ |
| Upadhyay SuketuDirector | Disposition to issuer | −796 | — | — | May 1, 2026 | Form 4 ↗ |
| Thornberry NancyDirector | Disposition to issuer | −398 | — | — | May 1, 2026 | Form 4 ↗ |
| Thornberry NancyDirector | Grant / award | +472 | $0.00 | $0 | May 1, 2026 | Form 4 ↗ |
| Schneider JenniferDirector | Disposition to issuer | −796 | — | — | May 1, 2026 | Form 4 ↗ |
| Schneider JenniferDirector | Grant / award | +472 | $0.00 | $0 | May 1, 2026 | Form 4 ↗ |
| MCKENZIE DIANADirector | Disposition to issuer | −796 | — | — | May 1, 2026 | Form 4 ↗ |
| MCKENZIE DIANADirector | Grant / award | +943 | $0.00 | $0 | May 1, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding VRTX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Growth Fund of America | 12.5M | $5.59B | 1.55% | May 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 8.1M | $4.00B | 0.17% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 6.6M | $3.27B | 0.20% | Jun 30, 2026 |
| Investment Co of America | 6.3M | $3.11B | 1.69% | Jun 30, 2026 |
| American Balanced Fund | 5.6M | $2.76B | 0.96% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 5.4M | $2.68B | 0.55% | Jun 30, 2026 |
| AMCAP Fund | 4.7M | $2.08B | 2.14% | May 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 3.5M | $1.73B | 0.20% | Jun 30, 2026 |
| New Perspective Fund | 3.4M | $1.67B | 0.98% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 3.1M | $1.53B | 0.20% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list VRTX's shares (CUSIP 92532F100), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming vertex pharmaceuticals as client
- TARPLIN, DOWNS & YOUNG, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2024 Q4 · BUD, HCR, MMM, TAX$80K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2024 Q3 · BUD, HCR, MMM, TAX$80K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2024 Q2 · BUD, HCR, MMM, TAX$80K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCVERTEX PHARMACEUTICALS INCORPORATED · 2024 Q1 · BUD, HCR, MMM, TAX$80K
Filing ↗ - ALSTON & BIRD LLPVERTEX PHARMACEUTICALS INCORPORATED · 2026 Q2 · BUD, HCR$50K
Filing ↗
Government Contracts
Federal awards to VERTEX PHARMACEUTICALS INC / MA · USAspending
No federal contract awards found for VERTEX PHARMACEUTICALS INC / MA.
U.S. Patents
Recent USPTO applications naming VERTEX PHARMACEUTICALS INC / MA
No USPTO patent applications found for VERTEX PHARMACEUTICALS INC / MA.
Annual Financials
From VRTX's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B |
| Operating income | $4.17B | -$232.9M | $3.83B | $4.31B | $2.78B |
| Net income | $3.95B | -$535.6M | $3.62B | $3.32B | $2.34B |
| Diluted EPS | $15.32 | -$2.08 | $13.89 | $12.82 | $9.01 |
| Operating cash flow | $3.63B | -$492.6M | $3.54B | $4.13B | $2.64B |
| Cash and equivalents | $5.08B | $4.57B | $10.37B | $10.50B | $6.79B |
| Total assets | $25.64B | $22.53B | $22.73B | $18.15B | $13.43B |
| Total liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B |
| Shareholders' equity | $18.67B | $16.41B | $17.58B | $13.91B | $10.10B |
As VERTEX PHARMACEUTICALS INC / MA tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 13, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitAug 24, 2000
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02Officer / director changeSep 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 8.01, 9.01Material agreement · Reg FD disclosure · Other eventsJul 7, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07Officer / director change · Shareholder voteMay 13, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 4, 2026
EDGAR ↗
About VERTEX PHARMACEUTICALS INC / MA
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersBOSTON, MA
IncorporatedMA
SEC CIK0000875320 ↗